Recent News
The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.Read Article
ICYMI: B Cells at the Brink in Sjögren Disease
A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.
Read Article
EULAR16: Reports on Systemic Sclerosis
EurekAlert!
In an oral abstract presentation on Thursday 4th June, results were shared from a longitudinal observational analysis of the EUSTAR database – a large multicentre online database that prospectively follows more than 25,000 patients across over 200 international centres. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity
Read Article
2-Gene Blood Test for Kawasaki Disease in Febrile Children
JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses.
https://t.co/Pwb23fOcO9 https://t.co/P6g23uJzNb
Dr. John Cush @RheumNow ( View Tweet)
True or False: A 5-year retrospective study found that platelet-rich plasma injections significantly outperformed NSAIDs when given to early knee osteoarthritis patients. See if you got it right in this week's RheumIQ quiz at https://t.co/Z8XFynKJ0o. https://t.co/Eu82fctE4B
Dr. John Cush @RheumNow ( View Tweet)
NEW FROM ACR: Clinical responses with an IL-23i in patients with active PsA
See the efficacy and safety data through ~5 years in the RheumNow poster hall. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/KfkpMpciEf https://t.co/X6aEOUNNbZ
Dr. John Cush @RheumNow ( View Tweet)
JAMA Review on Low Back Pain
A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain (nsLBP), drawing on 108 publications identified from a PubMed search (2005–2026) and the https://t.co/KCa97Pi1bj
Dr. John Cush @RheumNow ( View Tweet)
Missed a session at EULAR 2026?
No problem.
The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/nWCsuk8aPv
Dr. John Cush @RheumNow ( View Tweet)
Prospective study of 6 newly Dx RA pts starting MTX shows MTX causes a decline in T follicular helper (Tfh) cells and plasmablasts (@ wk 3 before clin response), selectively in responders but not nonresponders. MTX shifts cellular & gene expression towards a more physiological https://t.co/scmfAAE9XA
Dr. John Cush @RheumNow ( View Tweet)
#TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/h0oe3WksK1
Dr. John Cush @RheumNow ( View Tweet)
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases
The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/L5XRcIxl5s
Dr. John Cush @RheumNow ( View Tweet)
Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/31IRNXckym
Dr. John Cush @RheumNow ( View Tweet)
RHEUM SURVEY> When treating NON-RENAL lupus, is a drug with a "lupus nephritis indication" more likely to be used? Answer here >> https://t.co/1KridYM9n8 https://t.co/WiBhdKRxik
Dr. John Cush @RheumNow ( View Tweet)
Brenda McShan: The Creative Heart of RheumNow
A pivotal member of the RheumNow family, Brenda McShan, will be retiring with honors.
Read Article
Generic Tofacitinib (6.26.2026)
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.
Read Article
Throughout Gout Campaign Month, RheumNow is bringing together internationally recognized experts to explore the Systemic Burden of Gout through Rx Updates, QD Clinic case discussions, and expert Vlogs designed for practicing rheumatologists.
New educational content will release https://t.co/ZOQQuZinQd
Dr. John Cush @RheumNow ( View Tweet)
Bundibugyo virus disease (BVD) outbreak in the Congo in 2026. BV is an orthoebolavirus (not Ebola virus) species. Of the 2351 reported, 505 (22%)confirmed by PCR & 19% died. Sxs: Most 20-39 yrs, F>M, Fever (74%), GI & diarrhea (67%), anorexia, Abd pain (37%). HA (42%), SOB (34%), https://t.co/yYSmPjuiZW
Dr. John Cush @RheumNow ( View Tweet)
Where are we with Biomarkers in Rheumatoid Arthritis?
Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and https://t.co/ggoWx8yumZ
Dr. John Cush @RheumNow ( View Tweet)
B cell Targeting in SLE
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
https://t.co/wGaZPnXfID https://t.co/a0fNvdcrbQ
Dr. John Cush @RheumNow ( View Tweet)
RHEUM SURVEY> Do you prefer a lupus drug if it has a lupus nephritis indication (when your treating non-renal SLE)? Answer here >> https://t.co/1KridYM9n8 https://t.co/zIqNB5Mc0O
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Generic Tofacitinib (6.26.2026)
DERM on RheumNow (June 2026)-
Do You Zoster Vaccinate? (6.19.2026)
RheumNow EULAR 2026 Rheumatology Round Up
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
